<i>In Vivo</i> Application of an RNAi Strategy for the Selective Suppression of a Mutant Allele
-
- Takayuki Kubodera
- Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8519, Japan.
-
- Hiromi Yamada
- Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8519, Japan.
-
- Masayuki Anzai
- Institute of Advanced Technology, Kinki University, Kainan, Wakayama 642-0017, Japan.
-
- Shinga Ohira
- Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8519, Japan.
-
- Shigefumi Yokota
- Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8519, Japan.
-
- Yukihiko Hirai
- Department of Biochemistry and Molecular Biology, Nippon Medical School, Bunkyo-ku, Tokyo 113-8602, Japan.
-
- Hideki Mochizuki
- Department of Neurology, School of Medicine, Kitasato University, Sagamihara, Kanagawa 252-0374, Japan.
-
- Takashi Shimada
- Department of Biochemistry and Molecular Biology, Nippon Medical School, Bunkyo-ku, Tokyo 113-8602, Japan.
-
- Tasuku Mitani
- Institute of Advanced Technology, Kinki University, Kainan, Wakayama 642-0017, Japan.
-
- Hidehiro Mizusawa
- Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8519, Japan.
-
- Takanori Yokota
- Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8519, Japan.
この論文をさがす
説明
Gene therapy for dominantly inherited diseases with small interfering RNA (siRNA) requires mutant allele-specific suppression when genes in which mutation causes disease normally have an important role. We previously proposed a strategy for selective suppression of mutant alleles; both mutant and wild-type alleles are inhibited by most effective siRNA, and wild-type protein is restored using mRNA mutated to be resistant to the siRNA. Here, to prove the principle of this strategy in vivo, we applied it to our previously reported anti-copper/zinc superoxide dismutase (SOD1) short hairpin RNA (shRNA) transgenic (Tg) mice, in which the expression of the endogenous wild-type SOD1 gene was inhibited by more than 80%. These shRNA Tg mice showed hepatic lipid accumulation with mild liver dysfunction due to downregulation of endogenous wild-type SOD1. To rescue this side effect, we generated siRNA-resistant SOD1 Tg mice and crossed them with anti-SOD1 shRNA Tg mice, resulting in the disappearance of lipid accumulation in the liver. Furthermore, we also succeeded in mutant SOD1-specific gene suppression in the liver of SOD1(G93A) Tg mice, a model for amyotrophic lateral sclerosis, using intravenously administered viral vectors. Our method may prove useful for siRNA-based gene therapy for dominantly inherited diseases.
収録刊行物
-
- Human Gene Therapy
-
Human Gene Therapy 22 (1), 27-34, 2011-01
Mary Ann Liebert Inc